Table 2 Multivariable Cox proportional hazards model, propensity score-adjustment, and IPTW analyses of the effect of co-administration of PPIs on relapse-free survival of the entire population (capecitabine monotherapy and CapeOX regimen).

From: Proton pump inhibitors affect capecitabine efficacy in patients with stage II–III colorectal cancer: a multicenter retrospective study

     

Multivariable analysis

Adjusted for propensity score

IPTW

Variables

No.

Event

Censored

HR (95% CI)

P-value

Posterior probability

HR (95% CI)

P-value

Posterior probability

HR (95% CI)

P-value

Posterior probability

PPI

Yes

54

15

39

1.43 (0.81–2.51)

0.215

0.135

1.37 (0.79–2.41)

0.265

0.159

1.54 (0.85–2.80)

0.158

0.077

 

No

552

110

442

1

  

1

  

1

  

Age (10-year intervals)

0.89 (0.75–1.05)

0.178

       

Sex

Male

328

76

252

1.40 (0.97–2.01)

0.072

       

Female

278

49

229

1

        

Primary site

Right-sided colon

171

39

132

1.13 (0.77–1.67)

0.536

       

Others

435

86

349

1

        

Stage

III high-risk

199

67

132

2.33 (1.26–4.30)

0.007

       

III low-risk

334

45

289

0.78 (0.42–1.46)

0.443

       

II

73

13

60

1

        

Regimen

CapeOX

157

39

118

0.90 (0.59–1.38)

0.639

       

Capecitabine

449

86

363

1

        

RDI (10% intervals)

0.93 (0.86–1.01)

0.088

       
  1. Abbreviations: CapeOX, capecitabine and oxaliplatin; CI, confidence interval; HR, hazard ratio; IPTW, inverse probability of treatment weighting; PPI, proton pump inhibitor; RDI, relative dose intensity.